one of the asx200 poor performers, page-16

still waiting but hopeful The current issue with NRT and the OVATURE study is the FDA.

NRT are attempting to do a study that has never be undertaken before - resensitizing chemo-unresponsive, terminal cancer patients. The results are dependent on survivability and this sort of study could last for years. NRT are working with the FDA to determine what interim data thresholds would be suitable for PXD to be released to the market.

They are still hopefull that they can get FDA approval to start the phase III program soon.

G